In this module Patricia LoRusso DO PhDh reviews the current guidelines and recommendations for molecular testing in advanced BTC explains the rationale for targeting MDM2p53 signaling in BTC and provides expert perspectives on the potential future role of MDM2 inhibitors in BTC
- Provider:Clinical Care Options
- Activity Link: https://clinicaloptions.com/CE-CME/oncology/role-of-the-mdm2-p53-pathway-in-btc-1/26492-49016
- Start Date: 2024-08-29 05:00:00
- End Date: 2024-08-29 05:00:00
- Credit Details: AMA PRA Category 1 Credit™️: 1.0 hours
- Commercial Support: Source: Boehringer Ingelheim Pharmaceuticals, Inc. - Amount: 129070.0 - Is Kind Support: False
- Activity Type: Enduring Material
- CME Finder Type: Online Learning
- Fee to Participate: No, it's free
- Measured Outcome: Learner Knowledge, Learner/Team Competence
- Provider Ship: Directly Provided
- Registration: Open to all
Subscribe
Login
0 Comments
Oldest